Product Partnering

Product Partnering is our major thrust area and to facilitate this process. We partner major pharmaceutical companies in India & abroad as a reliable and efficient contract manufacturer.

The use of WINIMED SUSP 50 (Stanozolol Water Suspension) for the treatment of venous insufficiency

Venous insufficiency is often caused by blood clots. This is a very common disease during which the flow of blood through the veins is blocked, causing blood to pool in the legs. Untreated, venous insufficiency progress into chronic venous insufficiency with symptoms of leg pain, lipodermatosclerosis (inflammation of subcutaneous fat), different skin changes, such as erythema, pigmentation, increased risk of infection, white atrophy and a corona phlebectatica (ankle flare) can appear in the course of the disease. Chronic venous insufficiency (CVI) is a condition then brown-colored indurated patches, known as lipodermatosclerosis, are seen in long-standing cases. In the end-stage of this disease, a venous leg ulcer will occur.

Stanozolol is an androgen and anabolic steroid (AAS) medication which was derived from dihydrotestosterone (DHT). WINIMED SUSP 50 (Stanozolol Water Suspension) has been used in the treatment of venous insufficiency. Different randomized trials noted the improvement in the area of lipodermatosclerosis, reduced skin thickness, and possibly faster ulcer healing rates with WINIMED SUSP 50 (Stanozolol Water Suspension).

For example, patients with chronic venous insufficiency and changes such as dermal pericapillary fibrin cuffs participated in the recent research. It has been suggested that this fibrin deposition is responsible for an oxygen diffusion block, which in turn, leads to local hypoxia and ulcers. Sixty patients with lipodermatoscelerosis were chosen for this double-blind, placebo-controlled, randomized trial. Stanozolol 5 mg or a placebo tablet was given to them twice a day for 6 months. All patients were supplied with below-knee German/Swiss specification class 2 graduated compression stockings. The area of lipodermatosclerosis was measured once a month and transcutaneous oxygen tension within the liposclerotic area was measured every 3-months. The following results were shown: the control group showed a mean reduction in the area of lipodermatosclerosis of 14% (95% c.i.: -2.6-31%) compared with a 28% reduction in area in the active treatment group (95% c.i.: 5.3-46%).  Both groups showed no changes in transcutaneous oxygen measurements. The active treatment group experienced more side effects (P less than 0.02, Chi-squared). Although fibrinolytic enhancement caused a reduction in the area of lipodermatosclerosis, no evidence of any effect on a possible oxygen diffusion block was indicated.

WINIMED SUSP 50 (Stanozolol Water Suspension) stimulates blood fibrinolysis and can be successfully utilized for the treatment of the more advanced skin changes in venous disease such as lipodermatosclerosis.